Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients  by Wiegand, S.B. et al.
ORIGINAL ARTICLE VIROLOGYDominance of hepatitis C virus (HCV) is associated with lower quantitative
hepatitis B surface antigen and higher serum interferon-γ-induced protein
10 levels in HBV/HCV-coinfected patientsS. B. Wiegand1,2, J. Jaroszewicz1,3, A. Potthoff1, C. Höner zu Siederdissen1, B. Maasoumy1, K. Deterding1, M. P. Manns1,2,
H. Wedemeyer1,2 and M. Cornberg1,2
1) Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, 2) German Centre for Infectious Disease Research
(DZIF), partner site Hannover-Braunschweig, Germany and 3) Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok,
PolandAbstractDifferent viral dominance patterns have been documented in coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) based on HBV
DNA and HCV RNA quantiﬁcation. In most cases, HCV is dominant and suppresses HBV replication. In vitro studies revealed that there is most
probably no direct interference between HBV and HCV replication. We hypothesized that indirect mechanisms mediated by host immune
responses might be responsible for the different dominance patterns. In this study we analysed quantitative hepatitis B surface antigen (HBsAg)
as a marker for immune control of HBV and interferon γ-induced protein 10 (IP-10) as host marker for the endogenous interferon in 85
patients with HBV/HCV coinfection. Levels of HBsAg were closely associated with viral dominance patterns in 85 HBV/HCV-coinfected
patients. HBsAg levels were lowest in patients with HCV dominance, even lower compared with HBV-monoinfected patients undergoing
treatment with nucleos(t)ide analogues (NA) but comparable to low replicative HBsAg carriers. An increase in HCV RNA during follow up
was associated with HBsAg decline. Patients with HCV dominance had signiﬁcantly higher serum IP-10 levels compared with HBV-dominant
patients or HBV-monoinfected patients treated with NA. Lower HBsAg and higher IP-10 levels in HCV-dominant HBV/HCV-coinfected
patients suggest that HCV suppresses HBV DNA replication and also HBsAg production by immune mechanisms.
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S.B. Wiegand, J. Jaroszewicz and A. Potthoff contributed equally.IntroductionHepatitis B virus (HBV) and hepatitis C virus (HCV) share similar
modes of transmission and therefore a dual infection is frequent
in individuals with a high risk of parenteral infections, i.e. drug
users. Dual infection with HBV and HCV leads to a moreMicrobiol Infect 2015; 21: 710.e1–710.e9
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p://dx.doi.org/10.1016/j.cmi.2015.03.003progressive liver disease and is associated with a higher incidence
of hepatocellular carcinoma compared with HBV or HCV
monoinfection [1]. Although treatment of HBV and HCV mon-
oinfection is well established, only a few studies have systemat-
ically investigated treatment regimens for HBV/HCV-coinfected
patients [2]. Raimondo et al. showed that the virological patterns
in patients with HBV/HCV coinfection are divergent and vary
over time [3]. However, data suggest that HCV suppresses HBV
in most cases [3–5]. Hence, treatment with pegylated inter-
feron-α (IFN-α) and ribavirin primarily targeting HCV infection
was mostly used and resulted in sustained HCV response of
60–80% [2,6,7]. Treatment of chronic hepatitis C has dramati-
cally changed in the last few years and in 2015 interferon-free
therapies combining direct-acting antiviral agents such asiety of Clinical Microbiology and Infectious Diseases
CMI Wiegand et al. Quantitative HBsAg and IP-10 in HBV/HCV 710.e2protease inhibitors, polymerase inhibitors and NS5A inhibitors
can result in sustained virological response rates of >90% for
most patients [8]. However, the new interferon-free therapies
against HCV have not been tested yet in the setting of HBV/HCV
coinfection but may be as effective as in HCV monoinfection.
Importantly, it has been shown that successful elimination of
HCV can result in an increase or even reactivation of HBV
replication [5,9]. This highlights the complex interplay between
HBV and HCV. Despite the clinical impact of dual infection,
there is not much information about how both viruses interfere
with each other. Several studies demonstrated a suppressing
effect of hepatitis C core protein on HBV replication [10–13]. In
contrast Bellecave et al. have demonstrated that HBV and HCV
replicate in the same cell without evidence for direct interfer-
ence in vitro [14], which implies that indirect mechanisms
mediated by host immune responses might be responsible for
different dominance pattern of both viruses. Hence, investigating
viral and host biomarkers may achieve a better understanding of
the interplay between HCV and HBV.
Quantiﬁcation of hepatitis B surface antigen (HBsAg) as a
correlate for active intrahepatic covalently closed circular DNA
has recently become an increasingly central marker to describe
the natural course and treatment response of HBV infection
[15,16]. Importantly, data suggest a link between the immune
status and HBsAg concentrations. HBsAg seroclearance is
associated with the best outcome in HBV monoinfection and is
considered as deﬁnite immune control of HBV infection
[17,18]. Conversely, high HBsAg levels are associated with low
CD4 T-cell count in human immunodeﬁciency virus (HIV)/
HBV-coinfected patients, reﬂecting the importance of immune
responses for the control of HBV and the level of HBsAg [19].
A decline in HBsAg may also be induced by immunomodulation
with IFN-α [15,20], whereas this rarely occurs during treat-
ment with HBV reverse transcriptase inhibitors [21,22]. We
and others have recently suggested that high levels of IFN-
γ-inducible protein of 10 kDa (IP-10) may be useful to identify
patients who achieve an HBsAg decline during treatment with
nucleoside or nucleotide analogues (NA) [23,24]. Serum IP-10
has been discussed as a marker for an activated endogenous
interferon system that might predict response to exogenous
IFN-α treatment in patients with viral hepatitis. However,
although high IP-10 is a negative predictor for response to
treatment with IFN-α in HCV infection [25–27], this seems to
be different in HBV infection. Besides the above-mentioned
studies in NA-treated HBV patients, two other studies have
shown that high IP-10 levels are also associated with response
to IFN-α therapy in HBV infection [28,29].
We here investigated the role of HBsAg levels and of serum
IP-10 in HBV/HCV coinfection to increase our understanding of
the indirect interplay between HCV and HBV.© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of EuPatients and methodsPatients and study design
Eighty-ﬁve Caucasian patients with HBV/HCV coinfection pos-
itive for HBsAg and anti-HCV have been recruited in a single
university hospital over a period of 10 years (1998–2008).
None of the included patients received antiviral therapy at the
time-point of the cross-sectional analysis. Eighty per cent of
patients were hepatitis B e antigen (HBeAg) -negative. Four
patterns of viral dominance have been deﬁned according to
Raimondo et al. [3]: Group (a) HBV dominance with HBV DNA
>2000 IU/mL and HCV RNA <600 IU/mL; Group (b) HCV
dominance with HCV RNA >600 IU/mL and HBV DNA
<2000 IU/mL; Group (c) both viruses dominant with HBV
DNA >2000 IU/mL and HCV RNA >600 IU/mL; and Group (d)
no virus dominant with HBV DNA <2000 IU/mL and HCV
RNA <600 IU/mL. Baseline characteristics of HBV/HCV pa-
tients are presented in Table 1.
In 34 (56% HBeAg-negative) HBV/HCV-coinfected patients,
longitudinal data were available. During the median follow-up
duration of 4 years (range 1–12 years), 21 patients did not
receive antiviral therapy, seven patients were treated with
lamivudine, one patient was treated with famciclovir and ﬁve
patients received IFN-α-based therapy (one received pegylated
IFN plus ribavirin, four received recombinant IFN mono-
therapy). Serum for HBsAg measurement for an additional
follow-up time-point was available in 14 of 21 untreated
patients.
To obtain a deeper insight into the relevance of quantitative
HBsAg in HBV/HCV coinfection, two well-established cohorts
of patients with HBV monoinfection served as control groups.
HBsAg levels of 26 patients with low replicative chronic HBV
infection not receiving anti-HBV therapy and having a stable
HBV DNA <2000 IU/mL over a median period of 16 months
[16] and HBsAg levels of 64 patients with HBeAg-negative
chronic hepatitis B receiving NA treatment [22] were
compared with HBV/HCV-coinfected patients with HCV
dominance (Table 2).
None of the individuals included in the study had hepatitis δ
virus or HIV coinfection.
Deﬁnition of liver cirrhosis
Diagnosis of cirrhosis was either based on liver histology or
non-invasive methods such as ultrasound, FibroScan® or
biochemical results. Liver cirrhosis in biopsies was deﬁned as F4
in Metavir or F5-6 in Ishak. Liver stiffness 12.5 kPa was
considered as cirrhosis [30]. Patients with at least two of the
following criteria: platelets <100/nL, aspartate aminotrans-
ferase/alanine aminotransferase (ALT) ratio >1, bilirubin >1.5ropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 710.e1–710.e9










(n [ 18) pa
Age (years), median (10–90% CI) 40 (25–60) 37 (28–56) 43 (27–54) 39 (19–70) 38 (18–60) 0.41
Gender, n (M/F) 58/27 10/2 32/8 6/9 10/8 0.02
HBV DNA (log10 IU/mL), median (10–90% CI) 0.78 (0.78–6.85) 5.43 (4.35–7.14) 0.78 (0.78–1.18) 6.35 (4.08–7.36) 0.78 (0.78–2.00) <0.001
HBeAg+, n (%) 17 (20) 5 (42) 2 (5) 8 (53) 2 (11) <0.001
HCV RNA (log10 IU/mL), median (10–90% CI) 4.93 (0.77–6.24) 0.77 (0.77–0.77) 5.70 (4.74–6.39) 5.17 (3.34–6.54) 0.77 (0.77–2.74) <0.001
ALT (IU/mL), median (10–90% CI) 48 (21–216) 34 (12–3402) 54 (23–290) 48 (23–128) 47 (10–184) 0.51
AST (IU/mL), median (10–90% CI) 39 (14–143) 29 (15–1437) 46 (15–126) 40 (14–113) 32 (12–126) 0.77
GGT (IU/mL), median (10–90% CI) 55 (14–151) 34 (13–151) 57 (14–150) 54 (16–244) 49 (14–150) 0.67
Platelets (106/mL), median (10–90% CI) 172 (73–285) 165 (85–252) 154 (71–273) 230 (83–329) 199 (73–304) 0.43
Bilirubin (μmol/L), median (10–90% CI) 12.5 (5–56) 11 (7–210) 13 (5–34) 10 (5–91) 13 (7–46) 0.86
Cirrhosis, n (%)b 13 (15) 4 (33) 4 (10) 4 (27) 1 (6) 0.08
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; HBeAG, hepatitis B e antigen; HBV, hepatitis B virus; HCV, hepatitis C
virus.
aThe difference between different replication groups by use of analysis of variance or chi-squared test.
bDetermined by biochemical parameters and/or liver histology results.
710.e3 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIupper limit of normal range and albumin <35 g/L fulﬁlled the
biochemical assessment of cirrhosis. Individuals were consid-
ered to have cirrhosis if one of the deﬁnitions above was
satisﬁed.
HBsAg quantiﬁcation
Serum HBsAg levels were quantiﬁed using the Abbott AR-
CHITECT® assay (Abbott Diagnostics, Abbott Park, IL, USA).
The test has a dynamic range of 0.05–250 IU/mL. Samples
were diluted 1: 100 in horse serum and if quantitative HBsAg
results were >250 IU/mL samples were retested at a dilution
of 1: 500 and 1: 1000. Samples with HBsAg levels <0.05 IU/mL
have been retested without previous dilution. Results are
given in IU/mL [16]. The inter- and intra-assay variability is
<10% (6.7–8.8%), according to the manufacturer’s data sheet.
In 52 patients the sera were re-tested with Roche Elecsys II
assays (Roche, Basel, Switzerland) to conﬁrm and correlate
HBsAg levels with two independent assays as previously
described [31].
Measurement of HBV DNA and HCV RNA
The HCV RNA was quantiﬁed using the Cobas Amplipreb/
Cobas TaqMan® Assay v.1.0 and v.2.0 (Roche-Diagnostics,
Genzach-Whylen, Germany) with a lower limit of detection ofTABLE 2. Baseline characteristics HBV/HCV patients and HBV
patients on NA-therapy being HBV DNA <100 IU/mL)
b) HBV/HCV coinfection (n [ 40)
only HCV dominant
Age (years), median (10–90% CI) 44 (21–71)
Gender, n (M/F) 32/8
HBeAg+, n (%) 2 (5)
HBV DNA (log10 IU/mL), median (10–90% CI) 0.78
††† (0.78-1.51)
HBsAg (log10 IU/mL), median (10–90% CI) 2.88*** (–0.57 to 3.93)
Abbreviations: HBeAG, hepatitis B e antigen; HBsAG, hepatitis B surface antigen; HBV, hep
Mann–Whitney U test; ***p < 0.001 versus NA therapy, †††p < 0.001 versus low replicative
© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Soc15 IU/mL. HBV DNA was quantiﬁed with COBAS AmpliPrep/
COBAS TaqMan (Roche Diagnostics, Mannheim, Germany)
with a lower limit of detection of 6 IU/mL.
Serum cytokine analysis
Serum concentrations of IP-10 (CXCL-10) were assessed in
individuals with available serum using the Cytometric Bead
Array assay (CBA; BD Biosciences, Heidelberg, Germany) ac-
cording to the manufacturer’s protocol. Overall, serum samples
from 52 HBV/HCV-coinfected patients and 39 HBeAg-negative
patients before and during NA therapy were analysed. Sample
acquisition was performed using BD FACS Canto II (CBA; BD
Biosciences, Heidelberg, Germany) and analysed with FCAP
ARRAY (SoftFlow, Minneapolis, MN, USA).
Ethics approval
This retrospective study was conducted in accordance with the
guidelines of the Declaration of Helsinki, the principles of Good
Clinical Practice and according to standards of the local ethics
committee. All patients gave informed consent for the analysis
of parameters assessed during routine diagnostics, including
quantitative HBsAg measurement. Extra blood samples for the
analysis of serum cytokines were taken in patients who gave
informed consent for the immunological substudy. The studymonoinfected patients (low replicative and HbeAg-negative
e) HBV monoinfection on NA-therapy
(HBV DNA <100 IU/mL) (n [ 64)
f) HBV monoinfection with low
replication (n [ 26)
48 (33–65) 48 (31–59)
50/14 16/10
0 (0) 0 (0)
0.78 (0.78–2.0) 2.54 (1.76–3.17)
3.39 (2.39–4.10) 2.51 (0.75–2.87)
atitis B virus; HCV, hepatitis C virus; NA, nucleos(t)ide analogues.
.
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over Medical School, Hannover, Germany).
Statistical analyses
Serum HBsAg, HBV DNA and HCV RNA levels were loga-
rithmically transformed. Data are presented as medians
(10%–90% CI), unless indicated otherwise. Non-parametric
(distribution-free) tests were applied. Mann–Whitney U and
Kruskall–Wallis analysis of variance tests were used for uni-
variate and multivariate comparisons of independent contin-
uous variables, Spearman test for correlation analyses and
Fisher’s exact test for discrete variables comparison. Serum
HBsAg levels assessed by two different assays were compared
by Bland–Altman analysis. Statistical analysis was performed
using Statistica 9.1 (Statsoft, Tulsa, OK, USA).ResultsThe study cohort of HBV/HCV-coinfected patients consisted of
85 Caucasian patients (58 male, median age of 40 years) not
receiving antiviral therapy at the time of the cross-sectional
analysis. Seventeen (20%) patients were HBeAg positive, 43
(51%) had detectable HBV DNA, 62 (73%) had detectable HCV
RNA and 55 (65%) had increased ALT activity. Detailed
description of the studied population is given in Table 1.
Distribution of HBsAg levels in HBV/HCV coinfection
The median quantitative HBsAg level in the HBV/HCV cohort
was 3.50 log10 IU/mL (10%–90% CI 0.48–4.36). HBeAg-
positive patients had signiﬁcantly higher HBsAg compared
with HBeAg-negative patients (4.25 versus 3.19 log10 IU/mL,
p < 0.001). Similarly, patients with detectable HBV DNA
showed higher HBsAg compared with HBV DNA-negative pa-
tients (3.73 versus 3.00 log10 IU/mL, p < 0.01). Interestingly,
patients with detectable HCV RNA in serum showed lower
HBsAg than patients without HCV replication (3.20 versus 3.75
log10 IU/mL, p 0.08). Overall, HBsAg levels showed a positive
correlation with HBV DNA (r = 0.52, p < 0.001), whereas an
association with HCV RNA quantity tended to be negative
(r = –0.20, p 0.06), (Fig. 1a,b). Furthermore, HBsAg was
negatively associated with age of patients (r = –0.24, p 0.02).
On the other hand, HBsAg was not associated with ALT ac-
tivity, serum bilirubin, platelet count, HCV genotype and gender
(data not shown).
HBsAg levels and patterns of HBV/HCV replication
As HBsAg showed discordant correlation with HBV DNA and
HCV RNA in the overall cohort, we next analysed patterns of
HBV and HCV dominance in coinfected patients. Twelve© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of Eupatients (14%) showed HBV dominance (Group a) with HBV
DNA >2000 IU/mL and HCV RNA <600 IU/mL. The majority
of HBV/HCV-coinfected patients (n = 40, 47%) were HCV
dominant (Group b) with HBV DNA <2000 IU/mL and HCV
RNA >600 IU/mL. In 15 (18%) patients we observed a signiﬁ-
cant replication of both viruses (Group c) whereas in 18 (21%)
patients neither of the viruses was signiﬁcantly replicative ac-
cording to Raimondo et al. [3] (Group d) (Fig. 1a,b).
Patients in different groups of viral replication were largely
comparable for baseline characteristics, although male gender
was more prevalent in the HBV-dominant group (Table 1).
Distribution of HCV genotypes was similar (p 0.43). Interest-
ingly, HBsAg levels showed signiﬁcant differences between the
groups (analysis of variance, p < 0.001). As expected, HBsAg
levels were highest in patients with HBV DNA >2000 IU/mL
(Group a: 3.91 log10 IU/mL, Group c: 4.22 log10 IU/mL) and
lower in patients without HBV dominance (Group b: 2.88 log10
IU/mL, Group d: 3.25 log10 IU/mL) (Fig. 1c). Patients with HCV
dominance showed the lowest HBsAg levels of all groups
(Fig. 1c).
Quantitative HBsAg in patients with HCV/HBV
coinfection and HCV dominance
To better understand the relevance of the low HBsAg in
coinfected patients with HCV dominance, we compared HBsAg
levels of Group b with 64 HBeAg-negative HBV monoinfected
patients undergoing long-term therapy with NA and direct HBV
DNA suppression (Group e) (Table 2). This is a subgroup of the
cohort recently published [23]. Importantly, quantitative HBsAg
was signiﬁcantly higher in the NA-treated cohort compared
with the coinfected individuals with HCV dominance (Table 2).
Interestingly, analysis of HBsAg levels between HBV/HCV
coinfected patients with HCV dominance and 26 non-treated
HBV monoinfected patients with stable low replicative carrier
state (HBV suppression by the host immune response) revealed
comparable results (2.88 versus 2.51 log10 IU/mL, p 0.11)
(Fig. 1d).
Increase of HCV RNA is associated with decrease of
HBsAg in HBV/HCV-coinfected patients
Our cross-sectional analysis showed that HBsAg is suppressed
in coinfected patients with HCV dominance. Next we
addressed the question of whether dynamics in HCV RNA over
time alter HBsAg levels. In 14 of the 21 HBV/HCV patients not
undergoing antiviral treatment we analysed HCV RNA and
HBsAg over a period of 24 months (median). An HCV RNA
increase >1.0 log IU/mL was observed in 6/14 patients (Fig. 2a).
A t-test showed a signiﬁcant difference from baseline to follow-
up point between means of HCV RNA levels (3.20 log IU/mL
versus 6.36 log IU/mL; p 0.0319). This was associated with aropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 710.e1–710.e9
FIG. 1. Correlation of hepatitis B surface antigen (HBsAg) and (a) hepatitis B virus (HBV) DNA; (b) hepatitis C virus (HCV) RNA; (c) serum HBsAg
levels in HBV/HCV coinfection according to viral dominance (column a, HBV-dominant; b, HCV-dominant; c, both dominant; d, none dominant) and
(d) HBsAg levels in HCV dominant group versus HBV-monoinfected patients (column b, HCV-dominant HBV/HCV coinfection; e, HBV-monoinfected
patients after achieving viral response on nucleos(t)ide analogue (NA) therapy; f, HBV-monoinfected low replicative patients).
710.e5 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMImedian decrease in HBsAg of 1.73 log IU/mL (3.07 log IU/mL
versus 1.14 log IU/mL; p 0.0492). In contrast, 8/14 individuals
with no alteration in their HCV RNA levels (4.39 log IU/mL
versus 4.53 log IU/mL; p 0.8807) showed similar HBsAg values
at baseline and follow-up point (2.90 log IU/mL versus 2.97 log
IU/mL; p 0.9107) (Fig. 2b). The differences of HCV RNA and
HBsAg levels between baseline and follow up correlated
negatively (r = –0.77; p < 0.001) (Fig. 2c).
Serum IP-10 levels in HBV/HCV-coinfected patients
To understand possible mechanisms explaining different HBsAg
levels in different patient groups, serum IP-10 was studied in 52
HBV/HCV-coinfected patients. Nine patients belonged to
Group a (HBV dominance), 23 patients were HCV-dominant
patients (all HBeAg negative), 12 patients showed dominance
for both viruses, and eight patients were analysed from Group
d (no dominant virus). IP-10 level showed a positive correlation
with HCV RNA levels (r = 0.40, p 0.003) (Fig. 3a). Hence, pa-
tients with HCV dominance demonstrated a signiﬁcantly higher© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European SocIP-10 level compared with HBV-dominant patients (391.6
versus 160.8 pg/mL, p < 0.001) (Fig. 3b). We further compared
IP-10 level to 39 HBeAg-negative HBV-monoinfected patients.
HBV/HCV-coinfected patients with HCV dominance also had
signiﬁcantly higher IP-10 levels compared with HBeAg-matched
HBV-monoinfected patients before and during NA therapy
when HBV DNA was suppressed <100 IU/mL (391.6 versus
182.2 and versus 138.9 pg/mL, p < 0.001) (Fig. 3b). However,
HBeAg-negative HBV-monoinfected patients showing strong
HBsAg decline >1 log during NA therapy had the highest IP-10
levels comparable to those observed in the HCV-dominance
group of HBV/HCV-coinfected patients (baseline 589 pg/mL;
viral response 383 pg/mL).
Correlation between HBsAg measured with different
assays
In 52 HBV/HCV-coinfected patients HBsAg was quantiﬁed by
both the HBsAg Abbott Architect and the Roche Elecsys assays.
HBsAg measurements showed a strong positive correlationiety of Clinical Microbiology and Infectious Diseases, CMI, 21, 710.e1–710.e9
FIG. 2. The association between long-term
hepatitis C virus (HCV) RNA and hepatitis
B surface antigen (HBsAg) dynamics in hep-
atitis B virus (HBV)/HCV-coinfected patients
(a) with HCV RNA increase in follow up and
(b) with stable HCV RNA. Horizontal bars
denote median value at baseline (blue) and
last follow up (red). (c) Correlation between
’HCV RNA and ’HBsAg from baseline to last
follow up in HBV/HCV-coinfected patients.
CMI Wiegand et al. Quantitative HBsAg and IP-10 in HBV/HCV 710.e6(r = 0.96, p 10−30). An overall median HBsAg level in this
subgroup by Abbott Architect was 3.49 log10 IU/mL (minimum
–1.22, maximum 5.46) and by Roche Elecsys 3.73 log10 IU/mL
(minimum –1.22, maximum 5.52) with average bias of 0.10 (SD
0.34) log10 IU/mL (see Supporting information, Fig. S1).DiscussionThis study demonstrates that HBsAg levels are associated with
the viral dominance pattern in HBV/HCV-coinfected patients.
Interestingly, HBsAg levels were lowest in patients with HCV
dominance and an increase in HCV RNA levels over time was
associated with HBsAg decline. This suggests that HCV not only
has an impact on HBV DNA replication, as shown previously
[3], but also on HBsAg production, which is associated with
active intrahepatic covalently closed circular DNA [15,32].
Both HBV and HCV replicate in the same cell without evi-
dence for direct interference in vitro [14]. Our data also suggest© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of Euthat indirect mechanisms mediated by host immune responses
are responsible for different dominance patterns of both vi-
ruses. In this study, HCV dominant patients had the lowest
HBsAg values of all groups. Importantly, using follow-up data
we could show that there is strong correlation between HCV
RNA increase and HBsAg decline, further emphasizing a strong
connection between these two markers.
The HBsAg level in HCV-dominant patients were comparable
to low replicative inactive HBsAg carriers but signiﬁcantly lower
compared with HBeAg-negative patients with HBV DNA sup-
pression by direct antiviral NA therapy. This ﬁnding is in contrast
to HIV/HBV coinfection, where patients have higher HBsAg
levels compared with HBV-monoinfected patients with similar
HBV DNA levels [19], presumably as the result of HIV-induced
immunosuppression. Again this ﬁnding supports the hypothesis
that immune responses rather than direct viral interaction sup-
press HBV replication in HBV/HCV-coinfected patients.
Several data suggest that patients with chronic hepatitis C
have an activated or over-stimulated endogenous interferonropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 710.e1–710.e9
FIG. 3. (a) Correlation between baseline hepatitis C virus (HCV) RNA
and serum interferon γ-induced protein 10 (IP-10) in hepatitis B virus
(HBV)/HCV coinfection. (b) Serum IP-10 concentration in HBV/HCV
coinfection versus HBV-monoinfected patients (i, HBV-dominant HBV/
HCV coinfection: ii, HCV-dominant HBV/HCV co-infection; iii, HBV/
HCV dominant; iv, HBV monoinfection before nucleos(t)ide analogue
(NA) therapy; v, HBV monoinfection on NA at viral response; vi, HBV
monoinfection with hepatitis B surface antigen decline >1.0 log10 on NA
at baseline).
710.e7 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIsystem, reﬂected by overexpression of interferon-stimulated
genes [33] and also IP-10, which may inhibit the response to
exogenous IFN-α in this setting [25–27]. However, in HBV
infection, where the endogenous interferon system may not be
exhausted, high IP-10 levels may be one factor helping to
explain the suppressive effect of HCV on HBsAg. In line with
our hypothesis, HCV-dominant patients had signiﬁcantly higher
serum IP-10 levels. As shown for HCV-monoinfected patients
[25], we also found a positive correlation of IP-10 and HCV
RNA in HBV/HCV-coinfected patients. In addition, exogenous
IFN treatment leads to a greater suppression of HBsAg
compared with inhibition of the HBV reverse transcriptase by
NA treatment [20,34] and the rather rare event of HBsAg
decline during NA treatment is associated with higher serum
IP-10 levels >350 pg/mL before the start of NA therapy [23,24],
which also suggests that immune/cytokine responses are
important for the elimination or degradation of intrahepatic
covalently closed circular DNA [35]. Other data supporting the© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Soctheory that the HBsAg decline might be induced by indirect
immune mechanisms come from a study in HBsAg-positive
patients with acute HIV infection. Jiao et al. [36] have shown
that HBV DNA decreased during acute HIV infection and 40%
of the 25 patients underwent HBeAg loss and three individuals
achieved HBsAg loss.
What could be the clinical relevance of low quantitative
HBsAg in HBV/HCV-coinfected patients? HBV reactivation can
occur after successful elimination of HCV with interferon-based
therapy [5,9]. A recent study in HBV/HCV-coinfected patients
showed that an HBsAg decline >50% during therapy with
pegylated IFN-α and ribavirin was associated with a reduced
risk of HBV reactivation [37]. Higher HBsAg levels in HBeAg-
negative patients seem to be associated with HBV reactivation
during the natural course of HBV infection [15,16] and Bru-
netto et al. suggested a cut-off of <1000 IU/mL deﬁning HBsAg
carrier with a positive predictive value of 90% [38]. In this
study, 55% of HCV-dominant patients had HBsAg levels
<1000 IU/mL. However, it needs to be addressed in future
studies if those patients are protected from reactivation after
sustained elimination of HCV RNA.
A main limitation of our study is that the data have been
analysed retrospectively and the groups showed a mismatch
considering gender distribution. We have not analysed IP-10
levels from all of the HBV/HCV-coinfected patients because
of a lack of serum samples. Another limitation of our study is
that the study was not powered to correlate the virological
pattern with disease progression. Nevertheless, we here pro-
vide novel insights into the pathogenesis of HBV/HCV coin-
fection, which may have implications for clinical management.
We suggest that indirect immune mechanisms are responsible
for HBV suppression by HCV in HBV/HCV-coinfected patients.
Our data help to interpret quantitative HBsAg in the manage-
ment of HBV/HCV-coinfected patients. IP-10 should be further
evaluated in the setting of hepatitis B as a biomarker to predict
HBsAg decline as an important step toward cure of HBV
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